"The University of Colorado Hemophilia and Thrombosis Center (HTC) is located at the CU Medicine Anschutz Medical Campus in Aurora. We are the region's leader for the treatment of patients with bleeding and clotting disorders, and pediatric stroke. We serve patients in the Rocky Mountain region, including Colorado, Wyoming and Montana."

During the past decade, University of Colorado Hemophilia & Thrombosis Center conducted 18 clinical trials. In the 10-year time frame, 18 clinical trials started and 6 clinical trials were completed, i.e. on average, 33.3% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 3 clinical trials were completed. i.e. 60% of trials that started reached the finish line.

Out of the total clinical trials conducted in "University of Colorado Hemophilia & Thrombosis Center" #1 sponsor was "Baxalta now part of Shire" with 5 trials, followed by "National Institute of Allergy and Infectious Diseases (NIAID)" with 5 trials sponsored, "Pfizer" with 4 trials sponsored, "American Thrombosis and Hemostasis Network" with 3 trials sponsored and "Bayer" with 3 trials sponsored. Other sponsors include 3 different institutions and companies that sponsored additional 13 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "University of Colorado Hemophilia & Thrombosis Center" #1 collaborator was "Bristol-Myers Squibb" with 4 trials as a collaborator, "CSL Behring" with 3 trials as a collaborator, "Takeda" with 2 trials as a collaborator, "Takeda Development Center Americas, Inc." with 2 trials as a collaborator and "American Thrombosis and Hemostasis Network" with 1 trials as a collaborator. Other collaborators include 7 different institutions and companies that were collaborators in the rest 17 trials.

According to Clinical.Site data, the most researched conditions in "University of Colorado Hemophilia & Thrombosis Center" are "Hemophilia A" (9 trials), "HIV Infections" (5 trials), "Hemophilia B" (5 trials), "Hemophilia A With Inhibitors" (3 trials) and "Hemophilia" (2 trials). Many other conditions were trialed in "University of Colorado Hemophilia & Thrombosis Center" in a lesser frequency.

Most popular intervention types in "University of Colorado Hemophilia & Thrombosis Center" are "Drug" (12 trials), "Biological" (11 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "Didanosine" (4 trials), "Zidovudine" (4 trials), "PF-06741086" (2 trials), "Antihemophilic Factor (Recombinant)" (1 trials) and "Antihemophilic factor, recombinant, manufactured protein-free" (1 trials). Other intervention names were less common.

The vast majority of trials in "University of Colorado Hemophilia & Thrombosis Center" are 16 trials for "All" genders, 11 trials for "Male" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "University of Colorado Hemophilia & Thrombosis Center". undefined are not yet recruiting, 5 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 18 completed trials in University of Colorado Hemophilia & Thrombosis Center, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in University of Colorado Hemophilia & Thrombosis Center, 2 "Phase 1" clinical trials were conducted, 10 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".